Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 55: 1539-1545, 2009. First published June 18, 2009; 10.1373/clinchem.2009.124263
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
clinchem.2009.124263v1
55/8/1539    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Schwedhelm, E.
Right arrow Articles by Vasan, R. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwedhelm, E.
Right arrow Articles by Vasan, R. S.
(Clinical Chemistry. 2009;55:1539-1545.)
© 2009 American Association for Clinical Chemistry, Inc.

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Asymmetric Dimethylarginine Reference Intervals Determined with Liquid Chromatography–Tandem Mass Spectrometry: Results from the Framingham Offspring Cohort

Edzard Schwedhelm1,a, Vanessa Xanthakis2, Renke Maas1,3, Lisa M. Sullivan2,4, Friedrich Schulze1, Ulrich Riederer5, Ralf A. Benndorf1, Rainer H. Böger1 and Ramachandran S. Vasan4,6

1 Clinical Pharmacology Unit, Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2 Department of Biostatistics, Boston University School of Public Health, Boston, MA; 3 Institute of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen, Erlangen, Germany; 4 Framingham Heart Study, Framingham, MA; 5 Institute of Pharmacy, University of Hamburg, Hamburg, Germany; 6 Preventive Medicine and Cardiology Sections, Department of Medicine, Boston University School of Medicine, Boston, MA.

aAddress correspondence to this author at: Institute of Experimental and Clinical Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany. Fax 49-40-42803-9757; e-mail schwedhelm{at}uke.uni-hamburg.de.

Background: Accumulating evidence links higher circulating asymmetric dimethylarginine (ADMA) to greater risk of cardiovascular disease (CVD). Relatively small differences in ADMA concentrations between healthy individuals and those with disease underscore the need to formulate reference intervals that may aid risk stratification of individuals.

Methods: We formulated reference intervals for plasma ADMA concentrations using a community-based reference sample from the Framingham Offspring Study consisting of 1126 nonsmoking individuals [mean (SD) age 56 (9) years; 60% women] who were free of clinical CVD, hypertension, diabetes, and obesity and who attended a routine examination at which ADMA was assayed. ADMA concentrations were determined using a validated tandem mass spectrometry–liquid chromatography assay.

Results: In the study sample, the mean ADMA concentration was 0.52 (0.11) µmol/L, and the reference limits were 0.311 and 0.732 (2.5th and 97.5th percentile). The sex-specific reference limits were 0.310 and 0.745 in men and 0.313 and 0.721 µmol/L in women. In multivariable regression analysis, ADMA plasma concentrations were positively correlated with age and total plasma homocysteine (both P < 0.001).

Conclusions: Reference limits calculated for circulating ADMA in our large community-based healthy reference sample confirm the previous observation of a relatively narrow distribution of concentrations. This suggests a tight physiological control of ADMA plasma concentrations, presumably by dimethylarginine dimethylaminohydrolase (DDAH) metabolism of ADMA.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the American Association for Clinical Chemistry.